Open access

Patient-derived ascites reveals functional advantages of γδCAR T-cells within the ovarian cancer-like tumor microenvironment

Paula Hahn Katerina Ntarntani Isabella Micallef Nilsson Emilija Gailiesaite E. Foord Michael Uhlin Isabelle Magalhaes Thomas Poiret

Sep 2026 · bioRxiv · 0 citations

Biology

TL;DR

These findings reveal specific functional advantages of γδCAR T-cells over convCAR T-cells in the immunosuppressive OVCA TME-like condition while facing different cellular fitness constraints, providing insights into the use and limitations of γδCAR T-cells.

DOI Semantic Scholar

Read PDF

Similar papers

Sep 2026

Abstract B100: Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell–engineered mesothelin-redirected CAR-engineered invariant natural killer T cells

Pancreatic cancer (PC) remains one of the leading causes of cancer-related mortality worldwide, with most patients diagnosed at advanced stages and more than half presenting with metastatic disease at diagnosis. Although chimeric antigen receptor (CAR)-T cell therapy has shown promise for the treatment of PC, its cli...

Yan-Ruide Li, Xin-Yuan Shen, En-Bo Zhu et al. · Cancer Research · 0 citations

Open access Sep 2026

CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers

Abstract Background Ovarian and gastric cancers are associated with poor prognosis and derive limited benefit from current therapies, highlighting the need for novel immunotherapeutic approaches. The L1 cell adhesion molecule (L1CAM) is aberrantly expressed in several types of solid tumors and is associated with aggres...

X. Che, Un-Jung Yun, Junsub Lee et al. · Journal for ImmunoTherapy of... · 0 citations

Aug 2026

Humanized CD70-targeted CAR-T cells with reduced fratricide demonstrate potent antitumor activity against AML and RCC.

A humanized CD70-targeted CAR-T cell therapy is developed, A174-hu1-CAR-T, with reduced fratricide and potent antitumor activity, providing a preclinical foundation to support further translational development.

Meng-Jia Zhang, Zhi-Hao Wang, Cheng Gao et al. · International Immunopharmaco... · 0 citations

Open access Sep 2026

29 Engineering CD16-Enhanced Stem Cell–Derived Universal NKT Cells to Potentiate Anti-CD70 Therapy in Renal Cell Carcinoma

CD16HSC-NKT cells are established as a versatile and scalable cellular platform that synergizes with cusatuzumab to enhance therapeutic efficacy against RCC, and represent a promising approach to overcoming current limitations of monoclonal antibody therapy and advancing next-generation immunotherapies for solid tumors...

Yan-Ruide Li, Yi-Chen Zhu, Yu-Ning Chen et al. · The Oncologist · 0 citations

Open access Oct 2026

Metabolic Rewiring of GPC3-Targeted CAR T Cells Expressing IL-15 and HER2-Targeted CAR T Cells via the ADA1–CD26 Axis Promotes Tumor Infiltration and Limits Systemic Toxicities

Background: Chimeric antigen receptor (CAR) T-cell therapy for solid tumors is limited by inadequate T-cell persistence and tumor infiltration, as well as treatment-associated cytokine release syndrome (CRS). To address these challenges, we developed a metabolically rewired CAR T-cell (MRCAR) platform by co-expressing...

Yue Hu, Kevin Song, Ruo-Ning Wang et al. · Biomedicines · 0 citations

Open access Sep 2026

Preclinical evaluation of SLC35D3-targeted CAR-T cells for tumor-selective immunotherapy

Chimeric antigen receptor (CAR)-T therapy has transformed management of hematological malignancies, yet efficacy in solid tumors is limited by scarcity of tumor-restricted antigens. Here we characterize SLC35D3, a nucleotide-sugar transporter that we previously identified through integrated transcriptomic and protein-l...

Shunsuke Someya, Ming-Ma Ming, Wataru Tomisato et al. · Biochemistry and Biophysics... · 0 citations